1. Home
  2. GBDC vs IOVA Comparison

GBDC vs IOVA Comparison

Compare GBDC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBDC
  • IOVA
  • Stock Information
  • Founded
  • GBDC 2009
  • IOVA 2007
  • Country
  • GBDC United States
  • IOVA United States
  • Employees
  • GBDC N/A
  • IOVA N/A
  • Industry
  • GBDC Finance: Consumer Services
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GBDC Finance
  • IOVA Health Care
  • Exchange
  • GBDC Nasdaq
  • IOVA Nasdaq
  • Market Cap
  • GBDC 4.0B
  • IOVA 771.4M
  • IPO Year
  • GBDC 2010
  • IOVA N/A
  • Fundamental
  • Price
  • GBDC $14.77
  • IOVA $1.74
  • Analyst Decision
  • GBDC Buy
  • IOVA Buy
  • Analyst Count
  • GBDC 4
  • IOVA 10
  • Target Price
  • GBDC $15.50
  • IOVA $12.22
  • AVG Volume (30 Days)
  • GBDC 1.5M
  • IOVA 11.7M
  • Earning Date
  • GBDC 08-04-2025
  • IOVA 08-07-2025
  • Dividend Yield
  • GBDC 10.56%
  • IOVA N/A
  • EPS Growth
  • GBDC N/A
  • IOVA N/A
  • EPS
  • GBDC 1.18
  • IOVA N/A
  • Revenue
  • GBDC $830,269,000.00
  • IOVA $212,679,000.00
  • Revenue This Year
  • GBDC $21.93
  • IOVA $86.62
  • Revenue Next Year
  • GBDC N/A
  • IOVA $69.95
  • P/E Ratio
  • GBDC $12.47
  • IOVA N/A
  • Revenue Growth
  • GBDC 28.08
  • IOVA 11070.12
  • 52 Week Low
  • GBDC $12.68
  • IOVA $1.64
  • 52 Week High
  • GBDC $16.08
  • IOVA $12.51
  • Technical
  • Relative Strength Index (RSI)
  • GBDC 52.06
  • IOVA 38.67
  • Support Level
  • GBDC $14.23
  • IOVA $1.67
  • Resistance Level
  • GBDC $14.80
  • IOVA $1.82
  • Average True Range (ATR)
  • GBDC 0.28
  • IOVA 0.12
  • MACD
  • GBDC 0.00
  • IOVA -0.00
  • Stochastic Oscillator
  • GBDC 81.69
  • IOVA 13.85

About GBDC Golub Capital BDC Inc.

Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if rated. Maximum investment is done in USA and Canadian Companies, with maximum profit earned from those countries.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: